These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25078947)

  • 1. A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers.
    Tomescu C; Liu Q; Ross BN; Yin X; Lynn K; Mounzer KC; Kostman JR; Montaner LJ
    PLoS One; 2014; 9(7):e103209. PubMed ID: 25078947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease Progression in HIV-1-Infected Viremic Controllers.
    Groves KC; Bibby DF; Clark DA; Isaksen A; Deayton JR; Anderson J; Orkin C; Stagg AJ; McKnight A
    J Acquir Immune Defic Syndr; 2012 Dec; 61(4):407-16. PubMed ID: 22902723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers.
    Tomescu C; Duh FM; Hoh R; Viviani A; Harvill K; Martin MP; Carrington M; Deeks SG; Montaner LJ
    AIDS; 2012 Sep; 26(15):1869-78. PubMed ID: 22874514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8+ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles.
    Koofhethile CK; Ndhlovu ZM; Thobakgale-Tshabalala C; Prado JG; Ismail N; Mncube Z; Mkhize L; van der Stok M; Yende N; Walker BD; Goulder PJR; Ndung'u T
    J Virol; 2016 Aug; 90(15):6818-6831. PubMed ID: 27194762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers.
    Rosás-Umbert M; Llano A; Bellido R; Olvera A; Ruiz-Riol M; Rocafort M; Fernández MA; Cobarsi P; Crespo M; Dorrell L; Del Romero J; Alcami J; Paredes R; Brander C; Mothe B
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.
    Emu B; Sinclair E; Hatano H; Ferre A; Shacklett B; Martin JN; McCune JM; Deeks SG
    J Virol; 2008 Jun; 82(11):5398-407. PubMed ID: 18353945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment.
    Chehimi J; Azzoni L; Farabaugh M; Creer SA; Tomescu C; Hancock A; Mackiewicz A; D'Alessandro L; Ghanekar S; Foulkes AS; Mounzer K; Kostman J; Montaner LJ
    J Immunol; 2007 Aug; 179(4):2642-50. PubMed ID: 17675528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of HIV-1 Pathogenesis in Viremic Nonprogressors Is Independent of Gag-Specific Cytotoxic T Lymphocyte Responses.
    Salgado M; Garcia-Minambres A; Dalmau J; Jiménez-Moyano E; Viciana P; Alejos B; Clotet B; Prado JG; Martinez-Picado J
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients.
    Witwer KW; Watson AK; Blankson JN; Clements JE
    Retrovirology; 2012 Jan; 9():5. PubMed ID: 22240256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher SLPI expression, lower immune activation, and increased frequency of immune cells in a cohort of Colombian HIV-1 controllers.
    Taborda NA; Cataño JC; Delgado JC; Rugeles MT; Montoya CJ
    J Acquir Immune Defic Syndr; 2012 May; 60(1):12-9. PubMed ID: 22240462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.
    Pereyra F; Addo MM; Kaufmann DE; Liu Y; Miura T; Rathod A; Baker B; Trocha A; Rosenberg R; Mackey E; Ueda P; Lu Z; Cohen D; Wrin T; Petropoulos CJ; Rosenberg ES; Walker BD
    J Infect Dis; 2008 Feb; 197(4):563-71. PubMed ID: 18275276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly divergent patterns of genetic diversity and evolution in proviral quasispecies from HIV controllers.
    de Azevedo SSD; Caetano DG; Côrtes FH; Teixeira SLM; Dos Santos Silva K; Hoagland B; Grinsztejn B; Veloso VG; Morgado MG; Bello G
    Retrovirology; 2017 May; 14(1):29. PubMed ID: 28464889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV Antibody Profiles in HIV Controllers and Persons With Treatment-Induced Viral Suppression.
    Kammers K; Chen A; Monaco DR; Hudelson SE; Grant-McAuley W; Moore RD; Alter G; Deeks SG; Morrison CS; Eller LA; Blankson JN; Laeyendecker O; Ruczinski I; Eshleman SH; Larman HB
    Front Immunol; 2021; 12():740395. PubMed ID: 34512672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for innate immune system activation in HIV type 1-infected elite controllers.
    Krishnan S; Wilson EM; Sheikh V; Rupert A; Mendoza D; Yang J; Lempicki R; Migueles SA; Sereti I
    J Infect Dis; 2014 Mar; 209(6):931-9. PubMed ID: 24185941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients.
    Van Gulck E; Bracke L; Heyndrickx L; Coppens S; Atkinson D; Merlin C; Pasternak A; Florence E; Vanham G
    PLoS One; 2012; 7(5):e37792. PubMed ID: 22666392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers.
    Ferre AL; Lemongello D; Hunt PW; Morris MM; Garcia JC; Pollard RB; Yee HF; Martin JN; Deeks SG; Shacklett BL
    J Virol; 2010 Oct; 84(19):10354-65. PubMed ID: 20668079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers.
    Hunt PW; Hatano H; Sinclair E; Lee TH; Busch MP; Martin JN; McCune JM; Deeks SG
    Clin Infect Dis; 2011 Mar; 52(5):681-7. PubMed ID: 21245154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of NK Cell Subpopulations That Differentiate HIV-Infected Subject Cohorts with Diverse Levels of Virus Control.
    Pohlmeyer CW; Gonzalez VD; Irrinki A; Ramirez RN; Li L; Mulato A; Murry JP; Arvey A; Hoh R; Deeks SG; Kukolj G; Cihlar T; Pflanz S; Nolan GP; Min-Oo G
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30700608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Learning to Be Elite: Lessons From HIV-1 Controllers and Animal Models on Trained Innate Immunity and Virus Suppression.
    Sugawara S; Reeves RK; Jost S
    Front Immunol; 2022; 13():858383. PubMed ID: 35572502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters.
    Pereyra F; Palmer S; Miura T; Block BL; Wiegand A; Rothchild AC; Baker B; Rosenberg R; Cutrell E; Seaman MS; Coffin JM; Walker BD
    J Infect Dis; 2009 Sep; 200(6):984-90. PubMed ID: 19656066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.